Form 4: Vera Therapeutics Director Beth C. Seidenberg Sells Shares Under 10b5-1 Trading Plan

Director Beth C. Seidenberg of Vera Therapeutics, Inc. sold shares of Class A Common Stock on October 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On October 28, 2024, Beth C. Seidenberg, a director of Vera Therapeutics, Inc., sold shares of Class A Common Stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on June 19, 2024.
• A total of 15,000 shares were sold in multiple transactions at weighted-average prices of $48.0123 and $49.5406.
• Following the reported transactions, Seidenberg directly owns 131,553 shares of Class A Common Stock.
• Additionally, 4,012 shares are indirectly held through the Samuel B. Seidenberg Irrevocable Trust, for which Seidenberg and her spouse serve as trustees.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity under a pre-arranged plan. It doesn't inherently convey positive or negative sentiment, but rather reports factual transactions.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned to avoid accusations of trading on inside information. The use of a 10b5-1 trading plan provides a legal framework for insiders to sell shares at predetermined times and prices.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, potentially leading to a slight decrease in investor confidence.
• However, the existence of a 10b5-1 trading plan mitigates concerns about insider trading based on non-public information.

Key Dates